OBG3 globular head and uses thereof
View Patent ↗The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
1. An isolated polypeptide fragment of a full-length OBG3 polypeptide, wherein said polypeptide fragment consists of consecutive amino acids 84 to 244, 85 to 244, 110 to 244, 102 to 244, or 103 to 244 of SEQ ID NO:6.
2. The isolated polypeptide fragment of claim 1 , wherein said polypeptide fragment consists of consecutive amino acids 84 to 244 of SEQ ID NO:6.
3. The isolated polypeptide fragment of claim 1 , wherein said polypeptide fragment consists of consecutive amino acids 85 to 244 of SEQ ID NO:6.
4. The isolated polypeptide fragment of claim 1 , wherein said polypeptide fragment consists of consecutive amino acids 110 to 244 of SEQ ID NO:6.
5. The isolated polypeptide fragment of claim 1 , wherein said polypeptide fragment consists of consecutive amino acids 102 to 244 of SEQ ID NO:6.
6. The isolated polypeptide fragment of claim 1 , wherein said polypeptide fragment consists of consecutive amino acids 103 to 244 of SEQ ID NO:6.
7. A composition comprising a carrier and a polypeptide fragment consisting of consecutive amino acids 84 to 244, 85 to 244, 110 to 244, 102 to 244 or 103 to 244 of SEQ ID NO:6.
8. The composition according to claim 7 , wherein said polypeptide fragment consists of consecutive amino acids 84 to 244 of SEQ ID NO:6.
9. The composition according to claim 7 , wherein said polypeptide fragment consists of consecutive amino acids 85 to 244 of SEQ ID NO:6.
10. The composition according to claim 7 , wherein said polypeptide fragment consists of consecutive amino acids 110 to 244 of SEQ ID NO:6.
11. The composition according to claim 7 , wherein said polypeptide fragment consists of consecutive amino acids 102 to 244 of SEQ ID NO:6.
12. The composition according to claim 7 , wherein said polypeptide fragment consists of consecutive amino acids 103 to 244 of SEQ ID NO:6.
13. A method of lowering circulating free fatty acid levels in an individual comprising administering to said individual a composition comprising a carrier and a polypeptide consisting of consecutive amino acids 84 to 244, 85 to 244, 110 to 244, 102 to 244, 103 to 244, or 105 to 244 of SEQ ID NO:6.
14. The method according to claim 13 , wherein said polypeptide consists of consecutive amino acids 84 to 244 of SEQ ID NO:6.
15. The method of claim 14 , wherein said method further reduces body mass.
16. The method according to claim 13 , wherein said polypeptide consists of consecutive amino acids 85 to 244 of SEQ ID NO:6.
17. The method of claim 16 , wherein said method further reduces body mass.
18. The method according to claim 13 , wherein said polypeptide consists of consecutive amino acids 110 to 244 of SEQ ID NO:6.
19. The method of claim 18 , wherein said method further reduces body mass.
20. The method according to claim 13 , wherein said polypeptide consists of consecutive amino acids 102 to 244 of SEQ ID NO:6.
21. The method of claim 20 , wherein said method further reduces body mass.
22. The method according to claim 13 , wherein said polypeptide consists of consecutive amino acids 103 to 244 of SEQ ID NO:6.
23. The method of claim 22 , wherein said method further reduces body mass.
24. The method according to claim 13 , wherein said polypeptide consists of consecutive amino acids 105 to 244 of SEQ ID NO:6.
25. The method or claim 24 , wherein said method further reduces body mass.
26. The method of claim 13 , wherein said method further reduces body mass.